

NCIC CLINICAL TRIALS GROUP

**GENITOURINARY**

DISEASE SITE COMMITTEE MEETING AGENDA

DELTA CHELSEA HOTEL, TORONTO, ON

ROOM: WREN

SATURDAY, APRIL 27, 2013 – 11:00 AM – 3:45 PM

CHAIR: F. SAAD

(03:45 PM – 04:15 PM EXECUTIVE COMMITTEE MEETING – CLOSED)

**CME Credits:**

*Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.*

**Learning Objectives:**

- To understand and address, through clinical and translational research, the disease burden associated with genitourinary malignancies in Canada.
  - To review recent developments in the understanding of molecular biology and new therapeutics as these relate to genitourinary malignancies.
  - To update, review, and discuss recent results of clinical studies conducted by or in collaboration with NCIC Clinical Trials Group.
  - To provide a learning environment supportive to new investigators.
  - To understand and apply new clinical trial methodologies in the field of clinical research related to genitourinary malignancies.
- 

**11:00 pm WELCOME**

F. Saad

**11:10 pm NCIC CTG/INTERGROUP PHASE III TRIALS: OPEN**

PR.13 (RADICALS)/MRC PR.10

C. Catton/F. Saad

PRC.3/CALGB 90203 Neoadjuvant Docetaxel plus Androgen

F. Saad/M. Gleave

Deprivation prior to RP v.s. RP only

**NCIC CTG/INTERGROUP PHASE III TRIALS: CLOSED, PENDING ANALYSES**

BL.8/EORTC 30994

F. Saad/L. Wood

REC.2/ECOG E2805 Sunitinib/placebo vs.

M. Jewett/ L. Wood

Sorafenib/placebo vs. placebo in resected RCC

PRC.2/CALGB 90202 Early vs. Standard Zoledronic Acid

F. Saad

in CaP metastatic to bone

**11:30 pm NCIC CTG IND TRIALS: OPEN.**

IND.205: PX-866 in recurrent or metastatic CRPC

S. Hotte

IND.209: Reolysin in combination with docetaxel and prednisone

B. Eigl

or docetaxel and prednisone alone in metastatic CRPC

*continued on next page ...*

- 11:50 pm NCIC CTG IND TRIALS: CLOSED.**
- IND.195: A Phase II Study of SB 939 in Patients with CRPC B. Eigl
- 11:55 pm NCIC CTG IND REPORT** K. Chi
- 12:00 pm LUNCH**
- 1:30 pm UPDATE ON NCIC CTG APPROVED STUDIES**
- PR.15 Pilot Study of HDR Brachytherapy E. Vigneault/ A. Loblaw  
in Intermediate Risk CaP
- BL.12 A Phase II Randomized trial of Nab-Paclitaxel vs. K. Sridhar  
Paclitaxel in Second Line Metastatic Urothelial Carcinoma
- 1:50 pm CUOG Update**
- 2:00 pm Invited Lecture:** Personalized Genomic Approaches and R. Bristow  
Pathway Identification for Individualized Prostate Cancer Therapy
- 2:30 pm DOG REPORTS/NEW PROPOSALS**
- Localized Prostate Cancer A. Loblaw/ N. Fleshner  
Advanced Prostate Cancer K. Chi/ F. Saad  
Advanced Bladder S. North/W. Kassouf  
Kidney A. Kapoor/J. Knox  
Testes C. Kollmaannsberger/ P. Chung  
Superficial bladder A. So
- 3:45 pm Meeting Adjourned**

**3:45 PM – 4:15 PM EXECUTIVE COMMITTEE MEETING – CLOSED**